270 related articles for article (PubMed ID: 25686244)
1. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
[TBL] [Abstract][Full Text] [Related]
2. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
Liang D; Chen Q; Guo Y; Zhang T; Guo W
Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
[TBL] [Abstract][Full Text] [Related]
3. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
Ryan MR; Sohl CD; Luo B; Anderson KS
Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
[TBL] [Abstract][Full Text] [Related]
4. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
5. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
6. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Guffanti F; Chilà R; Bello E; Zucchetti M; Zangarini M; Ceriani L; Ferrari M; Lupi M; Jacquet-Bescond A; Burbridge MF; Pierrat MJ; Damia G
Neoplasia; 2017 Jan; 19(1):35-42. PubMed ID: 27988457
[TBL] [Abstract][Full Text] [Related]
8. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
9. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
10. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
11. Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1.
Yoza K; Himeno R; Amano S; Kobashigawa Y; Amemiya S; Fukuda N; Kumeta H; Morioka H; Inagaki F
Genes Cells; 2016 Oct; 21(10):1049-1058. PubMed ID: 27558949
[TBL] [Abstract][Full Text] [Related]
12. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
13. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
[TBL] [Abstract][Full Text] [Related]
14. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
15. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
16. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
18. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
Lu J; Zhou K; Yin X; Xu H; Ma B
Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
[TBL] [Abstract][Full Text] [Related]
19. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
20. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
